JP2020514284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514284A5 JP2020514284A5 JP2019535381A JP2019535381A JP2020514284A5 JP 2020514284 A5 JP2020514284 A5 JP 2020514284A5 JP 2019535381 A JP2019535381 A JP 2019535381A JP 2019535381 A JP2019535381 A JP 2019535381A JP 2020514284 A5 JP2020514284 A5 JP 2020514284A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- chloroisoquinoline
- alkyl
- picoline amide
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 substituted Chemical class 0.000 claims description 106
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 20
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 12
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 12
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 11
- 101000765010 Homo sapiens Beta-galactosidase Proteins 0.000 claims description 11
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229960003966 nicotinamide Drugs 0.000 claims description 10
- 235000005152 nicotinamide Nutrition 0.000 claims description 10
- 239000011570 nicotinamide Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- FTSCEGKYKXESFF-LXTVHRRPSA-N N-nonyldeoxynojirimycin Chemical compound CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO FTSCEGKYKXESFF-LXTVHRRPSA-N 0.000 claims description 4
- UQRORFVVSGFNRO-XFWSIPNHSA-N (2r,3s,4r,5s)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO UQRORFVVSGFNRO-XFWSIPNHSA-N 0.000 claims description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 2
- 108700023372 Glycosyltransferases Proteins 0.000 claims description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
- 102000005262 Sulfatase Human genes 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 claims description 2
- 229960001512 miglustat Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108060007951 sulfatase Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims 2
- 102000005431 Molecular Chaperones Human genes 0.000 claims 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 claims 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 230000004075 alteration Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 2
- 229940123064 Glycosyl transferase inhibitor Drugs 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 229940122344 Peptidase inhibitor Drugs 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382660.5 | 2016-12-28 | ||
| EP16382660 | 2016-12-28 | ||
| PCT/IB2017/058438 WO2018122746A1 (en) | 2016-12-28 | 2017-12-27 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514284A JP2020514284A (ja) | 2020-05-21 |
| JP2020514284A5 true JP2020514284A5 (https=) | 2021-02-12 |
| JP7144863B2 JP7144863B2 (ja) | 2022-09-30 |
Family
ID=57777485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535381A Active JP7144863B2 (ja) | 2016-12-28 | 2017-12-27 | イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11440898B2 (https=) |
| EP (1) | EP3562821B9 (https=) |
| JP (1) | JP7144863B2 (https=) |
| CN (1) | CN110494432B (https=) |
| AU (1) | AU2017388300B2 (https=) |
| BR (1) | BR112019013593A2 (https=) |
| CA (1) | CA3047700A1 (https=) |
| DK (1) | DK3562821T3 (https=) |
| ES (1) | ES2862374T3 (https=) |
| IL (1) | IL267553B (https=) |
| PL (1) | PL3562821T3 (https=) |
| PT (1) | PT3562821T (https=) |
| WO (1) | WO2018122746A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| WO2025094117A1 (en) * | 2023-11-02 | 2025-05-08 | Gt Gain Therapeutics Sa | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
| DE19740785A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Arylsulfonamide und Analoga |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| PT1254138E (pt) | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| WO2003022797A1 (en) | 2001-09-07 | 2003-03-20 | Seikagaku Corporation | Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| WO2004078114A2 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| CA2553969A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性のある阻害剤 |
| US20050250820A1 (en) | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| WO2006058201A2 (en) | 2004-11-23 | 2006-06-01 | Reddy Us Therapeutics, Inc. | Heterocyclic and bicyclic compounds, compositions and methods |
| KR20070094754A (ko) | 2004-12-01 | 2007-09-21 | 데브젠 엔브이 | 이온 채널, 특히 Ｋｖ 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체 |
| DK1838674T3 (da) | 2005-01-14 | 2011-06-14 | Chemocentryx Inc | Heteroarylsulfonamider og CCR2 |
| AT502145B1 (de) | 2005-03-24 | 2012-01-15 | Univ Graz Tech | Glycosidase-hemmendes iminoalditol |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| MX2008005814A (es) | 2005-11-03 | 2008-10-15 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| US20070179125A1 (en) | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
| CA2660421A1 (en) | 2006-08-10 | 2008-02-14 | Ferrer Internacional S.A. | 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
| EP1903034A1 (en) | 2006-09-19 | 2008-03-26 | Technische Universität Graz | Iminosugar glycoconjugates |
| WO2009042294A2 (en) | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| WO2009049421A1 (en) | 2007-10-18 | 2009-04-23 | The Hospital For Sick Children | Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
| SI2217572T1 (sl) | 2007-11-16 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto |
| ES2337435B8 (es) | 2008-10-22 | 2011-07-19 | Consejo Superior De Investigaciones Cientificas (Csic) (25%) | Compuestos potenciadores de la actividad de glicosidasas mutantes. |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| SI2995306T1 (sl) | 2009-10-19 | 2019-04-30 | Amicus Therapeutics, Inc. | Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR101987736B1 (ko) | 2011-03-18 | 2019-06-11 | 젠자임 코포레이션 | 글루코실세라마이드 합성효소 억제제 |
| WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
| BR112014015720B1 (pt) | 2011-12-30 | 2020-03-17 | Hanmi Pharm. Co., Ltd. | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase |
| RU2015113597A (ru) * | 2012-09-14 | 2016-11-10 | Итернити Байосайенс Инк. | Производные аминоизохинолина в качестве ингибиторов протеинкиназы |
| WO2014120995A2 (en) | 2013-02-01 | 2014-08-07 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
| WO2015014900A1 (en) * | 2013-07-31 | 2015-02-05 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
| AU2014347027A1 (en) | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | GSK -3 inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| AU2015249497A1 (en) | 2014-04-25 | 2016-10-20 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016120808A1 (en) * | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
-
2017
- 2017-12-27 WO PCT/IB2017/058438 patent/WO2018122746A1/en not_active Ceased
- 2017-12-27 EP EP17829043.3A patent/EP3562821B9/en active Active
- 2017-12-27 JP JP2019535381A patent/JP7144863B2/ja active Active
- 2017-12-27 BR BR112019013593-6A patent/BR112019013593A2/pt not_active IP Right Cessation
- 2017-12-27 CN CN201780086786.5A patent/CN110494432B/zh not_active Expired - Fee Related
- 2017-12-27 CA CA3047700A patent/CA3047700A1/en active Pending
- 2017-12-27 DK DK17829043.3T patent/DK3562821T3/da active
- 2017-12-27 PT PT178290433T patent/PT3562821T/pt unknown
- 2017-12-27 PL PL17829043T patent/PL3562821T3/pl unknown
- 2017-12-27 US US16/473,966 patent/US11440898B2/en active Active
- 2017-12-27 AU AU2017388300A patent/AU2017388300B2/en not_active Ceased
- 2017-12-27 ES ES17829043T patent/ES2862374T3/es active Active
-
2019
- 2019-06-20 IL IL267553A patent/IL267553B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI567067B (zh) | ＴｒＫ抑制化合物 | |
| EP1027050A2 (en) | Adenosine a3 receptor antagonists | |
| US9079889B2 (en) | Kinase inhibitors and methods of their use | |
| MX2012004662A (es) | Metodos de administracion de una terapia con pirfenidona. | |
| JP2005510473A5 (https=) | ||
| JP2008513516A5 (https=) | ||
| AR082458A1 (es) | Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 | |
| RU2014124101A (ru) | Использование тиено- и фуро- пиримидинов и пиримидинов в качестве ингибиторов калиевых каналов | |
| JP2020512343A5 (https=) | ||
| JP2016538313A5 (https=) | ||
| JP2010513448A5 (https=) | ||
| EP4233834A2 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks | |
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| WO2002051442A1 (en) | Concomitant drugs | |
| JP2019505595A5 (https=) | ||
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| RU2012108423A (ru) | Ацилгуанидиновые производные с азотсодержащим циклом | |
| JP2020514284A5 (https=) | ||
| HUP0301287A2 (hu) | Új gyógyszerészeti kombinációk NOS inhibitorként történő alkalmazásra | |
| JP2001114690A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤 | |
| JP2010513489A5 (https=) | ||
| AU2013232014A1 (en) | An iloperidone metabolite for use in the treatment of psychiatric disorders | |
| PE20071086A1 (es) | DERIVADOS DE PIRAZOLOISOQUINOLINA COMO INHIBIDORES DE LA CINASA p38 | |
| JP2023503465A5 (https=) |